Cocrystal Pharma, Inc. — Cash Flow Charts
8 years of history · ending 2020-12-31 · SEC EDGAR
Source:10-K · 10-Q
Capital Allocation
How management deploys cash: investing in the business (Capex + M&A) vs returning to shareholders (Buybacks + Dividends).
Capital Allocation Waterfall
Buybacks vs Stock-Based Comp
Net Debt Issuance
Cash Flow
Cash Flow by Activity
Operating Cash Flow↑+32.9% +$5M
$-10M
Free Cash Flow↑+31.5% +$5M
$-10M
Investing Cash Flow↓-8100.0% -$243K
$-240K
Financing Cash Flow↑+295.5% +$27M
$36M
Capex↑+370.6% +$189K
$240K
Stock-Based Comp↑+20.8% +$114K
$662K
Debt Repaid
$0
D&A↓-21.9% -$44K
$157K
SBC Allocated Expense↑+20.8% +$114K
$662K
SBC Unrecognized Cost
$11M